Combining Cadonilimab with Stereotactic Radiotherapy for Brain Metastases Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness and safety of Cadonilimab when used alongside stereotactic radiation therapy as a second-line treatment for brain metastases resulting from non-small cell lung cancer (NSCLC). The study aims to determine if this combination yields better outcomes compared to existing treatments and whether the associated toxicity is manageable. Participants will receive the treatment and undergo regular check-ups every 12 weeks to monitor their progress. The trial focuses on patients with specific criteria related to their cancer progression and treatment history.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18 years old ≤ 75 years old; Both male and female;
2. ECOG 0-1;
3. Histologically or cytologically confirmed non-small cell lung cancer;
4. Progression with brain metastasis after previous first-line anti-tumor therapy;
5. Requirements for brain metastases: ① measurable brain metastases without radiotherapy; ②SRS/FSRT: the maximum tumor volume of brain metastases was less than 10cm3, the single diameter was less than 3cm, and the total volume of brain metastases involved was less than 15 cm3.
6. Response to previous checkpoint inhibitor therapy on the initial response assessment;
7. If a metastatic lesion of the head has been irradiated, the cumulative radiation dose does not exceed the tolerated dose to all structures.
8. For patients with measurable CNS lesions, the longest diameter on MRI images is ≥10mm, which is suitable for repeated and accurate measurement.
9. Subjects were evaluated for all extracranial disease sites (e.g., by computed tomography (CT) scan and bone scan or positron emission tomography (PET-CT) within 14 days before the first dose.
10. Subjects had to have a baseline brain MRI scan within 14 days before the first dose of medication.
11. Estimated survival time \> 12 weeks.
12. Participants of childbearing age must agree to use effective contraception during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative.
13. Patients who are not lactating.
14. Have definite and good organ functions:
15. Provide informed consent voluntarily, and be willing and able to comply with the follow-up, treatment, laboratory testing, and other study requirements specified in the study schedule.

Exclusion Criteria:

Subjects who meet any of the following criteria are not eligible to participate in the study:

1. Experienced grade 3-4 intracranial toxicity (pituitary or central nervous system toxicity);
2. No measurable intracranial metastatic lesions without radiotherapy;
3. Meningeal metastasis;
4. If receiving chemotherapy or targeted therapy, the washout period should not exceed 3 weeks; if receiving brain metastasis resection, the washout period should not exceed 2 weeks;
5. Have significant autoimmune diseases
6. Prior treatment with a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor.
7. Previous (within 5 years) or concurrent other malignant tumors
8. History of anaphylaxis to any monoclonal antibody and/or study drug component.
9. A history of or current noninfectious pneumonia/interstitial lung disease requiring systemic glucocorticoids.
10. Serious infection within 4 weeks before the first dose.
11. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
12. Subjects required systemic treatment with corticosteroids (\>10mg prednisone equivalent per day) or other immunosuppressive drugs within 14 days before taking the study drug.
13. Patients with clinically significant cardiovascular disease
14. Enroll in another clinical study at the same time, unless it is an observational, noninterventional clinical study or a follow-up of an interventional study.
15. Received live vaccine within 30 days before the first dose, or planned to receive live vaccine during the study.
16. Known history of mental illness, substance abuse, alcohol or drug abuse.
17. Pregnant or lactating women.
18. The presence of any past or current medical conditions, treatments, or laboratory abnormalities may confound the results of the study, interfere with the full participation of the subject in the study, or may not be in the best interest of the subject to participate in the study.

Where it's running

• Xiangya Hospital, Central South University
  Changsha, Hunan, China Recruiting

Study contacts

• Study coordinator: Rongrong Zhou, MD, PHD
• Email: zhourr@csu.edu.cn
• Phone: +8613875898127

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• FAPI-guided radiotherapy with cadonilimab plus chemo for colorectal cancer limited to the peritoneum

  Aims to see if adding targeted radiotherapy and cadonilimab immunotherapy to standard second-line chemotherapy helps adults with colorectal cancer that’s spread only to the peritoneum.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07815834

• Ivonescimab in Neoadjuvant NSCLC: Testing a PD-1/VEGF Bi-specific

  This study tests Ivonescimab, a PD-1/VEGF bispecific antibody, in people with non-small cell lung cancer to see if it works better or has different safety than standard PD-1 inhibitors before surgery.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07359040

• Exercise training and the immune response in lung cancer

  This study tests whether a 12-week moderate or high-intensity exercise program can change the immune markers in people with non-small cell or small cell lung cancer who are receiving standard care.

  Recruiting Medical University of Graz · Graz · NCT07267000

• Datopotamab-deruxtecan with carboplatin and pembrolizumab for treatment‑naive NSCLC that has spread to the brain

  This trial will try giving datopotamab-deruxtecan together with carboplatin and pembrolizumab to adults with metastatic non‑small cell lung cancer that has spread to the brain and has no targetable mutations.

  Recruiting at 13 sites Phase 2 Latin American Cooperative Oncology Group · Fortaleza, Ceará and 12 other locations · NCT06822543

• Neoadjuvant Cemiplimab + Dupilumab in Early-Stage NSCLC

  This study tests whether giving cemiplimab with dupilumab before surgery can be safe and help shrink tumors in people with early-stage non-small cell lung cancer.

  Recruiting Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Quebec and 1 other locations · NCT06743581

• Combining SRT and Anlotinib for treating brain metastases from lung cancer

  This study is testing if combining a targeted cancer drug called Anlotinib with a type of focused radiation therapy can help patients with non-small cell lung cancer who have limited brain metastases and haven't responded to other treatments.

  Recruiting The First People's Hospital of Lianyungang · Lianyungang, Jiangsu · NCT06476093

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.